RGD Reference Report - Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia.

Authors: Zhang, G  Liu, A  Zhou, Y  San, X  Jin, T  Jin, Y 
Citation: Zhang G, etal., J Ethnopharmacol. 2008 Feb 12;115(3):441-8. Epub 2007 Oct 25.
RGD ID: 2290557
Pubmed: PMID:18083315   (View Abstract at PubMed)
DOI: DOI:10.1016/j.jep.2007.10.026   (Journal Full-text)

ETHNOPHARMACOLOGICAL RELEVANCE: Ginsenosides, the major active ingredients of Panax ginseng, produce a variety of pharmacological or physiological responses with effects on the central and peripheral nervous systems. AIM OF THE STUDY: In this report, we investigated the effects of ginsenoside Rg2 on cerebral ischemia-reperfusion induced impairment of neurological responses, memory and caudate-putamen neuronal apoptosis in a vascular dementia (VD) rat model. MATERIALS AND METHODS: Neurological evaluation was performed 24h after reperfusion and Y-maze memory performance was assessed at 48 h after reperfusion. Immunocytochemical techniques were employed to check the protein expression of BCL-2, BAX, heat shock protein 70 and P53, which are related with cell apoptosis. RESULTS: Neurological responses and memory ability of the ginsenoside Rg2 or nimodipine groups improved significantly compared with the VD group. The expression of BCL-2 and HSP70 were decreased, while BAX and P53 were increased in the VD model. The expression of BCL-2 and HSP70 proteins were increased, while BAX and P53 decreased after ginsenoside Rg2 (2.5, 5 and 10mg/kg) and nimodipine (50 microg/kg) treatment compared with the VD group. The study suggests that ginsenoside Rg2 improved neurological performance and memory ability of VD rats through mechanisms related to anti-apoptosis. CONCLUSIONS: The capacity for ginsenoside Rg2 to modulate the expression of apoptotic related proteins suggests that ginsenoside Rg2 may represent a potential treatment strategy for vascular dementia or other ischemic insults.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Reperfusion Injury  ISOBax (Rattus norvegicus)2290557; 2290557protein:increased expression:brainRGD 
Reperfusion Injury  IEP 2290557protein:increased expression:brainRGD 
transient cerebral ischemia  ISOBcl2 (Rattus norvegicus)2290557; 2290557protein:decreased expression:brainRGD 
transient cerebral ischemia  IEP 2290557protein:decreased expression:brainRGD 
vascular dementia  ISOTp53 (Rattus norvegicus)2290557; 2290557protein:increased expression:brainRGD 
vascular dementia  IEP 2290557protein:increased expression:brainRGD 

Objects Annotated

Genes (Rattus norvegicus)
Bax  (BCL2 associated X, apoptosis regulator)
Bcl2  (BCL2, apoptosis regulator)
Tp53  (tumor protein p53)

Genes (Mus musculus)
Bax  (BCL2-associated X protein)
Bcl2  (B cell leukemia/lymphoma 2)
Trp53  (transformation related protein 53)

Genes (Homo sapiens)
BAX  (BCL2 associated X, apoptosis regulator)
BCL2  (BCL2 apoptosis regulator)
TP53  (tumor protein p53)


Additional Information